Jazz Pharma initiates rolling submission to FDA for defibrotide for hepatic Veno-Occlusive Disease
Jazz Pharmaceuticals plc announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States FDA for defibrotide for the treatment of severe hepatic Veno-Occlusive Disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. Defibrotide has been granted Fast Track Designation to treat severe VOD by the FDA.
Jazz Pharmaceuticals has acquired the rights to defibrotide in the U.S. and other markets in North America, South America and Central America. Jazz Pharmaceuticals markets defibrotide in Europe under the name Defitelio (defibrotide). Defitelio is the first and only licensed product in Europe for the treatment of severe hepatic VOD in patients over one month of age undergoing HSCT therapy.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)